Medicines and Healthcare products Regulatory Agency (MHRA) Statutory Good Clinical Practice (GCP) Inspection of Cardiff University.

Slides:



Advertisements
Similar presentations
Managing Compliance Related to Human Subjects Research Review Joseph Sherwin, Ph.D. Office of Regulatory Affairs University of Pennsylvania Fourth Annual.
Advertisements

What FDA Looks for When Inspecting IRBs and Sponsors Marian J. Serge Nurse Consultant Division of Bioresearch Monitoring Office of Compliance Center for.
Briefing on MHRA routine inspection of non-commercial clinical trials
Research Policy & Management RACD INTRODUCTION TO RESEARCH GOVERNANCE.
Essential Documentation GCP Training Seminar 12th October 2011
Good Clinical Practice in Research Clinical Trial Regulations
Timelines Trust informed June 2007
CROMS NIDCR Clinical Monitoring
Tips to a Successful Monitoring Visit
Checking & Corrective Action
New Trials If you are seeking a collaboration with the UCL CCTU we require you to apply: At least 3 months before the application deadline By using the.
HOT TOPICS ARCHIVING OR HOW NOT TO DUMP YOUR RUBBISH!
GCP for Investigators Tina Lidén Mascher, Kvalitetsregister, forskning och industrisamarbeten.
Audit Ebru Mutlu-Omega CRO. General Purpose to help quality (to maintain quality at present) to assure quality (make sure that quality in future is maintained)
Kenya AIDS Vaccine Initiative
A Blueprint For Clinical Research: Standard Operating Procedures
Monitoring and Auditing
Practical Effective Steps to Improve Trial QUALITY from Audit/Inspections findings Cancer Clinical Trials Unit Scotland A NCRI Accredited Cancer Trials.
Cheryl McCarthy Manager, Quality Assurance MBC Session October 3, 2008 GCP Compliance in our Vendors.
ICH GCP, the MHRA and PATHOLOGY PATHOLOGY QUALITY ASSURANCE Rob Wosley MRQA SEPTEMBER 2009.
Developed by Klinikos; Roy Fraser (2012) Investigator Study File
Managing Sponsorship Research Services University of Oxford.
Learning from GMP Inspections. Richard Bateman QA Specialist Pharmacist East and South East England Specialist Pharmacy Services.
Tipologie di Audit e loro caratteristiche Riunione sottogruppo GCP-GIQAR 21 Marzo 2006 Francesca Bucchi.
© Safeguarding public health Lynne Byers An Introduction to MHRA and GCP Inspections – Lynne Byers Medicines and Healthcare products Regulatory Agency.
Session 6: Data Integrity and Inspection of e-Clinical Computerized Systems May 15, 2011 | Beijing, China Kim Nitahara Principal Consultant and CEO META.
Personnel Basic Principles of GMP Workshop on
Community Planning Training 1-1. Community Plan Implementation Training 1- Community Planning Training 1-3.
GIQAR Annual Congress 25 – 26 th May Pv QA: Quality Assurance for Pharmacovigilance Allison Jack Manager, R&D Oversight – GCP/PV, Pfizer Ltd BARQA.
Regulatory Update Ellen Leinfuss SVP, Life Sciences.
Regulatory Overview.
Elements of Clinical Trial Quality Assurance Regulatory Coordinator –SCTR SUCCESS Center QA Monitor – NIDA Clinical Trials Network Stephanie Gentilin,
MODULE I Close-Out Visit/Monitoring Reports Jane Fendl April 24, Versions: Final 24-Apr-2010.
© Imperial College LondonPage 1 Controls Assurance and Institutional Risk Management Gary Roper Research Governance Manager.
Joint Research & Enterprise Office Training The team, the procedures, the monitor and the Sponsor Lucy H H Parker Clinical Research Governance Manager.
CCAB Training Providers Event 17 November 2008 Reviews Required by QAC Heather Briers Director Chartered Accountants Regulatory Board.
University of Miami Office of Research Compliance Assessment Lynn E. Smith, JD, CIM, CIP Johanna Stamates, RN, BA, CCRC With assistance from Elizabeth.
Monitoring IRB Monitoring of Clinical Trials. Types of Monitoring Internally Internally Externally Externally.
CLINICAL TRIALS – PHASE III. What are phase III trials  Confirmatory phase (Therapeutic confirmatory trial)  Trials are done to obtain sufficient evidence.
UC DAVIS OFFICE OF RESEARCH Overview of Good Clinical Practices (GCP) Investigator and Study Team Responsibilities Miles McFann IRB Administration Training.
Conducting Clinical Risk Assessments And Implementing Compliance Practices Jane L. Stratton Chiron Corporation VP/Associate General Counsel Chief Compliance.
Basic Principles of GMP
Organization and Implementation of a National Regulatory Program for the Control of Radiation Sources Inspection Part III.
FDA Regulatory and Compliance Symposium
RIHES-II: H ANDLING A UDITS AND I NSPECTIONS E FFECTIVE D ATE 25 D ECEMBER 2006 V ERSION : 3.0 บุญเหลือ พรึงลำภู 15 มกราคม 2557.
Good Clinical Practice (GCP) UKTMN 6 th June 2006.
CONDUCTING COMPLIANCE ASSESSMENTS Allen Ditch Director Corporate Quality Bristol Myers Squibb Medical Research Summit March 6, 2003.
Quality & Regulatory Expectations of Outsourcing Oversight Nicky Dodsworth, VP Global Quality Assurance.
Verification, Validation and Internal Audits - Jose Jimenez Federal Facilities Program Manager – EPA Region III.
Korea Food & Drug Administration Deputy director Kwang-Soo Joo Korea FDA Sep. 29, 2000 : Korean Good Clinical Practice & Relative Guidelines How to Manage.
Surviving CTIMPs and MHRA inspections Kim Gooding Diabetes and Vascular Medicine UEMS and Exeter CRF Exeter Clinical Research Facility.
Good Laboratory Practice - general information Pirkko Puranen Senior Inspector, Ph.D. Inspectorate.
Responsibilities of Test Facility Management, Study Director, Principal Investigator and Study Personnel G. Jacobs Belgian GLP Monitorate Zagreb, 17 December.
GCP (GOOD CLINICAL PRACTISE)
Site Set-up and Conduct Caroline O’Leary and Carrie Bayliss.
Responsibilities of Sponsor, Investigator and Monitor
Briefing on MHRA routine inspection of non-commercial clinical trials
Post MHRA Inspection What next?
Lisa Hoebelheinrich, JD, CHRC Associate Vice Chancellor, Compliance
Responsibilities of Sponsor, Investigator and Monitor
Safety Reporting V6.0 17/01/17.
MAINTAINING THE INVESTIGATOR’S SITE FILE
MHRA GMP Inspection Deficiency Data Trend 2016
UK Legal Requirement for Notification of Serious Breaches of Good Clinical Practice or The Trial Protocol John Poland, PhD Senior Director, Regulatory.
MAINTAINING THE INVESTIGATOR’S STUDY FILE
Neopay Practical Guides #2 PSD2 (Should I be worried?)
Pharmacovigilance inspections: what HPRA expects
Quality Assurance in Clinical Trials
Good clinical practice
S A Overarching SOPs Funding Secured Training Records
Presentation transcript:

Medicines and Healthcare products Regulatory Agency (MHRA) Statutory Good Clinical Practice (GCP) Inspection of Cardiff University

Preparing for the Inspection Experience of an inspection The plan for today The inspectors Inspection process Inspection Outcomes Preparing for the Inspection Experience of an inspection

Group Manager Inspections The Inspectors GCP Inspectors Offices: York Welwyn Garden City Market Towers GMP Inspectors Group Manager Inspections GLP Inspectors GPvP Inspectors Expert Inspectors Serious Breach of GCP

What does an inspection involve? http://www.mhra.gov.uk/CON2024532

Pre-Inspection Dossier Complete list of Clinical Trials (from May 2005) Organisational charts Overview of all facilities Description of archiving arrangements SOP index Detailed procedures in relation to: Trial management Quality control and assurance Computerised systems Equipment maintenance Supply of Investigation Medicinal Product Laboratory procedures Activities carried out by CU or contracted out by CU

Clinical Trial Activities Any activity involved in the running of Clinical trials at our institution Archiving SOPs Statistics Adverse Event reporting Contracts Data Management Drug Management Trial reporting Project Management Training Laboratory Randomisation Computer Systems Regulatory approvals Study Monitoring Trial Files

What happens during the visit? 1 week inspection by at least 2 GCP Inspectors Documentation review University/School/Unit SOPs Facility Visits Inspection of several clinical trials to test systems Interviews with key personnel, e.g. Chief / Principal Investigator Research teams e.g. Research Fellow, Research Nurse RACD Laboratories IT Archiving facilities Inspection plan can change So what is likely to happen during the visit? We would expect at least 2 GCP inspectors to be on site. They may wish to see a tour of some of the facilities e.g. the CRF, pharmacy, laboratories etc. They may ask to see additional documentation not submitted as part of the Pre-Inspection Dossier – for example other policies or SOPs . As you can imagine, we had to be selective as to what we included in one lever arch file. They will want to inspect several clinical trials to test systems. These could be studies which are ongoing or studies that have closed since May 2005. If they decide they are particularly interested in close down or archiving systems they may well choose a study that has closed. Who will they wish to interview? Well of course we can’t be certain but from past experience, for the chosen trials they will usually interview the Chief/Principal Investigator and other key members of the same research team. They usually interview these individuals separately. We expect they will interview key individuals in the R&D Office and probably key individuals in Pharmacy, the laboratories, medical records, IT, radiology. As this is a statutory inspection, individuals are expected to make themselves available. As there is usually 4-6 weeks notice, clinicians would be expected to make alternative arrangements for clinics, ward rounds etc. The R&D office will of course do everything it can to try and schedule the timetable of interviews to suit both the MHRA AND staff here at the Trust. Once we know which studies are to be inspected in detail, we will ask for a named contact in the trial team to liaise with the R&D office over the logistics of the Inspection as we will be expected to provide suitable rooms for interview, access to office space and access to photocopiers etc. A member of the R&D Office will attend each interview as notes must be taken.

Inspection outcomes 3 categories of findings: Critical: evidence that i) the safety, well-being or confidentiality of trial subjects have been or have potential to be jeopardised, ii) the clinical trial data are unreliable iii) there are a number of Major non-compliances, indicating a systematic quality assurance failure. insufficient or untimely corrective action regarding previously reported Major non-compliances Major: significant and unjustified departure from legislative requirements that may develop into a critical issue unless addressed, a number of departures from legislative requirements and/or established GCP guidelines, indicating a systematic quality assurance failure. Other: departure from legislative requirements and/or established GCP guidelines, but it is neither Critical nor Major.

Response to Findings Organisation must respond within 30 days Critical Findings or a number of Major Findings may lead to suspension of one or all CTIMPs in the organisation Organisation response Analysis of findings Corrective Action Preventative Action Plans of assessing effectiveness of preventative action Timelines Disputed findings

Common Findings Contract & Agreement Preparation Lack of written agreements with collaborators Inconsistencies between protocol and contract Delegation of duties without agreements/systems in place Lack of identification of CI and all trial team at outset Quality System Lack of SOPs Insufficient time between issuing and implementing SOPs, leading to training issues Team meetings not documented Training Inadequate knowledge of Clinical Trial Regulations Lack of GCP training amongst trial team Informed Consent No record of consent Incorrect version

Common Findings Investigational Medicinal Product (IMP) management Inadequate provisions for storage of IMPs Insufficient records for the chain of custody Inadequate procedures for QP release Lack of documentation confirming role of Pharmacy/CI Pharmacovigilance Inadequate Pharmacovigilance systems and/or inadequate use of systems in place Lack of awareness of legislative requirements Standardisation or arrangements for un-blinding SAEs arising from blinded trials Annual safety report to MHRA not made Data management Security of trial documents/data Inadequate retention period Lack of clarity of data entry and data query processes (Source Data Verification)

Common Findings Information Management Lack of assurance that systems are fit for purpose Lack of evidence of system security No clarity on arrangements for backing up data Regulatory Affairs (e. g. Clinical Trial Authorisations) Remarks on MHRA approval letters not followed up Unclear indemnity arrangements Unclear sponsorship arrangements for DDX studies Annual and end of study reports not sent Filing of essential documents Poorly maintained site files Poor document control and management Forms not signed or not completed correctly Laboratory No evidence of how equipment is maintained, calibrated and serviced

University (RACD) Preparations Pre-Inspection Dossier Awareness Raising Delegation of duties Review of Clinical Trial list Clinical Trial Monitoring Visits - essential documentation MHRA Inspection working group Risk Assessment/GAP analysis – based on common findings from previous MHRA inspections Individualised preparation plans

How can Research Groups/Units prepare? Awareness raising Familiarity with legislation, internal and external guidance ICH GCP (Topic E6) http://www.emea.europa.eu/pdfs/human/ich/013595en.pdf University Research Governance web page http://www.cf.ac.uk/racdv/resgov/index.html www.ct-toolkit.ac.uk GAP analysis Essential documentation / Unit SOPs Action plan

How can Researchers prepare? Familiarity with legislation, internal and external guidance ICH GCP (Topic E6) http://www.emea.europa.eu/pdfs/human/ich/013595en.pdf University Research Governance web page http://www.cf.ac.uk/racdv/resgov/index.html www.ct-toolkit.ac.uk Essential Documentation - Self-assessment of the trial using Trial Master File checklist Approvals Document Control IMP management Delegation Logs SOPs Pharmacovigilance Equipment

Summary Anyone involved in Clinical Trials Co-operation and engagement Early Preparation Action plan to remedy issues

Contacts Research Governance Team resgov@cardiff.ac.uk X79277 (01798 79277 from Heath) Chris Shaw Matthew Harris Kathy Pittard Davies

Medicines and Healthcare products Regulatory Agency (MHRA) Statutory Good Clinical Practice (GCP) Inspection of Cardiff University